Overview

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

Status:
Completed
Trial end date:
2019-12-21
Target enrollment:
Participant gender:
Summary
With the PK of centanafadine currently being evaluated in adults. The PK of extended-release centanafadine may differ in children compared to adults due to physiological differences in the gastrointestinal tract. The information in this trial will support pediatric dose selection in future trials.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.